ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Baseline predictors of (A) ASDAS ID and (B) ASAS PR at week 12 of

AS Criteria: Diagnosis (ASAS), Disease Activity (ASDAS), Radiographic Progression (mSASSS) - Arthritis Rheumatism

Axial Spondyloarthritis RINVOQ® (upadacitinib)

Disease Control Data, Ankylosing Spondylitis

PDF] ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis

Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review - ScienceDirect

Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension - Deodhar

Disease Control Data, Ankylosing Spondylitis